
Mina Fam, MD, reviews risk-based PSA interpretation, prostate MRI, biomarkers, and targeted biopsy in the modern diagnostic pathway.









Mina Fam, MD, reviews risk-based PSA interpretation, prostate MRI, biomarkers, and targeted biopsy in the modern diagnostic pathway.

A urologist discusses how primary care clinicians can identify patients most likely to benefit from prostate cancer screening while limiting overdiagnosis.

Rodica Di Lorenzo, MD, of the Cleveland Clinic, reviews hypertension, lipids, diabetes, smoking, atrial fibrillation, and wearables in first-stroke prevention.

The proportion of US women aged 21 to 29 years who have never received cervical cancer screening more than doubled between 2005 and 2023, according to new data.

Stepped reminders to PCPs and patients increased annual lung cancer screening adherence by 27.7 percentage points, according to new research.

The US FDA granted breakthrough device status to Freenome’s investigational blood test designed to triage high-risk adults for lung cancer screening.

Fendrick considers the current state of colorectal cancer screening in the US, emphasizing limited colonoscopy capacity and patient preferences for at-home tests.

The 2026 global status report on cancer projects nearly 35 million new cases annually by 2050 and underscores urgent action on prevention and care access.

Survey finds nearly 18 million women aged 45 to 64 years are overdue for cancer screening.

Xavier Llor, MD, of Yale Medicine, discusses what the updated guidance from the American Cancer Society on colorectal cancer screening mean for primary care.

ACS updated colorectal cancer screening guidance, reaffirming screening at age 45 and adding newer stool-based and blood-based options.

ACOG 2026: James A. Simon, MD, discusses off-label evidence for elinzanetant in breast cancer survivors on anti-estrogenic therapy.

ACP Internal Medicine Meeting 2026 highlights: new mammography guidelines, AI scribe limitations, and muscle loss risks with GLP-1 weight loss drugs.

ACP guidance recommends biennial mammography for women aged 50-74 and shared decision-making for screening in women aged 40-49.

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.

In 142 000 adults, adding Galleri to standard screening reduced stage IV diagnoses over time in a prespecified group of 12 cancers, according to new data.

Physician researcher Fendrick offers an expert perspective on why removing cost barriers matters, and why navigation and patient realities still determine whether CRC screening succeeds.

GRAIL advances cancer detection with FDA application for Galleri, a groundbreaking blood test aimed at early detection of multiple cancers.

Colorectal cancer emerges as the top cancer killer for US adults under 50, highlighting urgent needs for early detection and screening strategies.

This episode reviews intranasal epinephrine use, pediatric atopic dermatitis data, dementia screening tools, adolescent TMS, and oral PCSK9 therapy.

Your daily dose of the clinical news you may have missed.

Psychiatrist Gus Alva, MD, discusses newer, faster depression screening approaches that primary care clinicians can implement.

Fendrick discusses the balance between colonoscopy and non-invasive tests for colorectal cancer screening, aiming for better patient outcomes.

Completion of the screening pathway—not test selection alone—may define quality going forward.

Moving patients from considering screening to completing it remains the central challenge in colorectal cancer prevention, Fendrick explained to Patient Care.